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Cutaneous leishmaniasis (CL) is a neglected parasitic disease conventionally 
treated by multiple injections with systemically toxic drugs. Aiming at a more 
acceptable therapy, we developed lipid-core nanocapsules (LNC) entrapping 
the potent antileishmanial chalcone (CH8) for topical application. Rhodamine-
labeled LNC (Rho-LNC-CH8) was produced for imaging studies. LNC-CH8 and 
Rho-LNC-CH8 had narrow size distributions (polydispersity index < 0.10), with 
similar mean sizes (~180 nm) by dynamic light scattering. In vitro, Rho-LNC-
CH8 were rapidly internalized by extracellular Leishmania amazonensis 
parasites macrophages in less than 15 minutes. LNC-CH8 activated 
macrophage oxidative mechanisms more efficiently than CH8, and was more 
selectively toxic against the intracellular parasites. In vivo, topically applied Rho-
LNC-CH8 efficiently permeated mouse skin. In L. amazonensis-infected mice, 
LNC-CH8 reduced the parasite load by 86% after three weeks of daily topical 
treatment, while free CH8 was ineffective. In conclusion, LNC-CH8 has strong 
potential as a novel topical formulation for CL treatment.  
 
Keywords: Leishmaniasis, nitrochalcone, lipid-core nanocapsules, drug 













Cutaneous leishmaniasis (CL) is the most common clinical form of the 
disease, accounting for an estimated 1.2 million cases per year, mainly in 
developing countries1. After inoculation of flagellated promastigotes into the skin 
by blood-feeding sandflies, successful parasites invade dermal macrophages, 
transform into amastigote forms, and survive and multiply intracellularly by 
downregulating host cell defense mechanisms such as the production of 
reactive oxygen species (ROS) and nitric oxide (NO), and proteolytic digestion 
inside the parasitophorous vacuole2. Chronic and disfiguring ulcers develop at 
the infection site, and may spread to other parts of the skin.    
Although the infection is limited to the skin, current CL chemotherapy 
involves long-term intravenous or intramuscular injections with pentavalent 
antimonials (Pentostam® or Glucantime®), pentamidine or amphotericin B. The 
injections are painful, systemically toxic and result in high hospital costs.3 The 
only oral antileishmanial drug – miltefosine – is used mostly for visceral 
leishmaniasis in the Old World, and is not approved for use in New World 
countries such as Brazil. To circumvent these difficulties, an effective topical 
treatment is the obvious choice for CL. However, creams containing 
paromomycin, miltefosine and amphotericin B have shown partial or no efficacy 
against CL, in particularly against New World Leishmania species4-6. Failure of 
topical formulations is typically linked to poor skin permeation, mainly to high 
drug molecular size and/or inappropriate lipophilicity7. The addition of strong 
permeation enhancers to topical formulations allows drugs to reach the deep 












the treatment site8. Thus, the present scenario justifies the search for new 
antileishmanial agents and formulations, particularly for topical CL treatment.  
Due to the inadequacy of current CL chemotherapy, the Drugs for 
Neglected Disease initiative (DNDi) has supported the search for new topical or 
oral treatments for CL that are efficacious against all species, easy to 
administer, can be given in as a short treatment course (14-28 days), and are 
compatible with combination therapy and adapted to tropical climates9. We 
have previously reported the strong antileishmanial activity and selectivity of the 
synthetic chalcone CH810 (3-nitro-2-hydroxy 4,6-dimetoxychalcone, Figure 1), a 
lipophilic and highly stable compound that fulfills most of the criteria specified by 
DNDi for a promising anti-leishmanial drug. In vivo, CH8 given to mice by the 
oral route is effective and safe against both cutaneous and visceral 
leishmaniasis11. Importantly, local subcutaneous injections with CH8 either in 
the free form10 or loaded in slow-release systems12, 13 effectively treated mice 
with CL. However, effective topical formulations remain a challenge for this and 
other anti-leishmanial compou ds. 
Drug nanocarriers have been extensively applied to improve drug 
delivery and bioavailability of molecules with poor solubility in water, such as 
chalcones. These systems may protect the drug against degradation while 
promoting its intestinal uptake or skin permeation through the epidermis layer or 
hair follicle14. Lipid-core nanocapsules (LNCs) made with a biodegradable 
poly(-caprolactone) shell have emerged as appropriate nanocarriers to 
increase the bioavailability of lipophilic agents, since these can be entrapped 
into the carrier lipid core15. Previously, we showed that encapsulation in LNC 












fold the efficacy of this lipophilic molecule via the oral route, in a murine model 
of CL.16 In topical drug delivery assays, LNCs successfully promoted skin 
permeation of other lipophilic molecules such vitamin K1, resveratrol and 
curcumin17, 18, without appreciable skin irritation.  
Given the efficacy of CH8 against CL and the safety and potential of 
LNCs as nanocarriers of drugs to the skin, we describe here the development 
and testing – both in vitro and in vivo - of an LNC-CH8 formulation for the 
topical treatment of CL.  
 
METHODS 
Animals and ethics statement 
BALB/c mice (female, eight-week-old, 23 g) used in the experiments 
were maintained under controlled conditions at the animal facilities of the 
Federal University of Rio de Janeiro (UFRJ, RJ, Brazil). 
The animal protocols used in this study were approved by the local 
Animal Care and Use Committee (protocol number CAUAP118). All animal 
experiments were conducted in compliance with the principles stated in the 
Guide for the Care and Use of Laboratory Animals, 8th Edition.19 
 
Production of lipid-core nanocapsules 
The compound 3-nitro-2-hidroxy-4,6-dimethoxy chalcone (CH8, Figure 1) 
was synthesized as described previously10.  
Lipid-core nanocapsules (LNC) were prepared by a self-assembly 












Sigma-Aldrich Co., USA), 80 mg sorbitan monostearate (Sigma-Aldrich Co.), 
310 mg capric/caprylic triglyceride (Alpha Quimica, Brazil) were dispersed in 
acetone (46 mL), and then injected into an aqueous phase composed of 
polysorbate 80 (185 mg; Gerbras, Brazil), ethanol (8 mL) and water (106 mL). 
The mixture was stirred for 10 minutes at room temperature, the solvent was 
evaporated under reduced pressure (rotatory evaporator, Büchi, Switzerland) at 
40 0C and the aqueous suspension was concentrated for a final volume of 10 
mL. Streptomycin (100 μg/mL) and penicillin (100 UI/mL) (Sigma-Aldrich Co.) 
were added. LNC-CH8 was prepared by adding 5 mg CH8 in the organic phase 
and Rho-LNC-CH8 was prepared as described above, with the exception that 
part of the unlabeled PCL was replaced with 10 mg of Rhodamine B-labeled 
PCL (Rho-PCL)21.  
 
Characterization of lipid-core nanocapsules 
 Formulations were analyzed by laser diffraction, in a Mastersizer® 2000 
particle size analyzer (Malvern, UK)15, to determine their volume-weighted 
mean diameter (D[4,3]). Size polydispersity was calculated considering the 
diameters at 10%, 50%, and 90% of the cumulative size distribution (SPAN). 
The Z-average diameter (method of cumulants) and polydispersity index were 
determined by photon correlation spectroscopy (PCS) using a Zetasizer Nano 
ZS particle analyzer (Malvern, UK) after dilution. The zeta potential of 
nanoparticles was calculated by examining the electrophoretic mobility of 
formulations dispersed in a 10mM NaCl aqueous solution (pH = 7.0) using a 














CH8 encapsulation efficiency 
A sample of the formulation was dissolved in acetonitrile and filtered 
(0.45 μm, Merck Millipore, USA). The CH8 content was quantified by HPLC-UV 
[Perkin-Elmer® S200 pre-column, column LiChrospher 100 RP18 (5µm) 
(Merck®)], using a mobile phase of acetonitrile:aqueous 0.01% phosphoric acid 
(Tedia) (80:20 v/v), with a flow rate of 1 mL/min and a detection wavelength of 
337 nm, as described previously.22 
Parasites 
Leishmania amazonensis (MHOM/BR/75/Josefa strain) promastigotes were 
maintained in culture at 26oC in M199 medium (CultiLab, Brazil) supplemented 
with 10% heat-inactivated fetal calf serum (HIFCS) (CultiLab, Brazil), 0.2% 
hemin (Sigma-Aldrich Co., USA), 100 g/mL streptomycin and 100 UI/mL 
penicillin (Sigma-Aldrich Co., USA), herein referred to as ‘complete medium’. 
Alternatively, GFP-expressing parasites were cultured as described previously23 
Parasites were always used at the stationary phase of growth.  
Anti-amastigote activity 
 Bone marrow derived macrophages (BMDM) from BALB/c mice were 
prepared as described23 and plated (2x105/ well) onto circular glass coverslips 
in 24-well culture plates, and incubated for 24 h at 37oC (and 5% CO2). Then 
macrophage monolayers were kept uninfected or were infected with L. 
amazonensis promastigotes (5x106 cells/ mL) for 4 h at 34oC / 5% CO2. After a 
further 24h of infection at 37oC, macrophages were incubated with 0.1, 1, 10 












48h at 37oC. Then, cells were washed with PBS and stained with panoptic 
(Instant Prov kit, Newprov, Brazil) according to the manufacturer’s instructions. 
The number of amastigotes in 200 cells was counted by light microscopy 
examination, in a Nikon Eclipse Ti microscope, at 1000 X magnification. The 
compound concentrations required to reduce amastigote numbers by 50% (IC50 
values) were calculated by linear regression analysis. 
Cytotoxicity 
 The supernatants of the anti-amastigote assay were collected at the end of 
the treatment described above and the release of the cytosolic enzyme lactate 
dehydrogenase (LDH) by the macrophages was used as a cytotoxicity indicator. 
For total and spontaneous LDH releases, supernatants were collected from 
cells cultured with 1% triton and medium alone, respectively. LDH release was 
measured by a colorimetric assay using the detection kit DHL (Doles, Brazil), 
according to the manufacturer’s instructions. Readings were taken at 492 nm in 
PowerWave XS spectrophotometer (BIO-TEK, USA), and cytotoxicity to BMDM 
calculated as the % of specific LDH release = (test - spontaneous / total - 
spontaneous) x100. The compound concentrations required to produce 50% of 
cytotoxicity (CC50 values) were calculated by linear regression analysis. The 
selectivity index (SI) for each compound was calculated as the ratio between 
50% cytotoxicity (CC50) and 50% anti-amastigote activity (IC50). 
Rho-LNC-CH8 uptake assays  
 For Rho-LNC-CH8 uptake by promastigotes, parasites (106 cells/mL), were 
plated in 24 well-plates in M199 medium containing 10% HIFCS, in the 












incubation, cells were washed with phosphate-buffered saline (PBS) and 
transferred to glass slides for visualization in an Eclipse-Ti fluorescence 
microscope (Nikon) equipped with a CFI Plan Apo Lambda 100X Oil objective. 
Standard filters for FITC (B-2A) or rhodamine (G2 E/C) and DIC were used. 
Images were analyzed using the Adobe Photoshop CC software (version 
14.2.1). Alternatively, fluorescent cells were analyzed by flow cytometry in a 
FACScan equipment (BD Biosciences), and the results were expressed as the 
percentage of cells (as gated by FSC vs. SSC) with fluorescence above 6x100 
arbitrary units (105 events/sample). 
 For LNC-CH8 uptake by macrophages and intracellular amastigotes, 
BMDM (2x105 cells/well) were infected as described for the anti-amastigote 
activity assay. After 24 h, infected and non-infected macrophages were treated 
with Rho-LNC-CH8 (10 g/mL CH8) for up to 240 min and cells were imaged by 
fluorescence microscopy as described above. Alternatively, BMDM were 
infected and treated in 6-well plates (at 106 cells/well), and then subjected to 
flow cytometry analysis as described above.  
Macrophage reactive oxygen species (ROS) production 
BMDM (1x105 cells/well) were plated into black, clear-bottom 96-well 
plates, and then infected with L. amazonensis promastigotes and treated with 
CH8, LNC-CH8, or LNC as described above for the anti-amastigote assay. 
Then, cells were incubated with the oxidation-sensitive fluorescent dye 2',7'-
dichlorodihydrofluorescein diacetate (H2DCFDA, at 10 µM; Invitrogen, USA) for 
20 min at 37°C, and fluorescence was read at 485/528 nm (excitation/emission) 












macrophages incubated with 250 µg/mL Zymosan (Sigma–Aldrich Co.) were 
used as positive controls for ROS production.  
Macrophage nitric oxide (NO) production 
BMDM (1x105 cells/ well) were plated in 96-well plates, and then infected 
with L. amazonensis promastigotes and treated with CH8, LNC-CH8, or LNC as 
described above for the anti-amastigote assay. NO production in culture 
supernatants was measured by the Griess method, as described previously24. 
Readings were taken at 570 nm in a PowerWave XS spectrophotometer (BIO-
TEK, USA). The nitrite concentration was calculated using a standard curve of 
sodium nitrite (NaNO2), from 0 to 50 µM. Uninfected and infected macrophages 
incubated with 1 µg/mL lipopolysaccharide (LPS; Sigma–Aldrich Co.) were used 
as positive controls for NO production.  
Macrophage intracellular proteolysis 
BMDM (1x105 cells/well) were plated in black clear bottom 96-well plates, 
maintained and infected as described above for the anti-amastigote activity 
assay. At 24 h after infection, cells were incubated with CH8 (1 µg/mL), LNC-
CH8 or LNC for 20 min at 37°C. Then, cells were allowed to internalize the 
fluorogenic protein substrate DQ green-BSA (Thermo Fisher, UK) and human 
IgG (Sigma-Aldrich) - functionalized carboxylated silica beads (Kisker Biotech 
GmbH & Co., Germany) (5:1) for 5 minutes, as described previously25. Alexa 
Fluor 594 succidinimyl ester (Molecular Probes, USA) was used as a calibration 
fluorophore. After washing in PBS (to remove non-phagocytosed beads), the 
increase in fluorescence, indicative of proteolysis, was measured at different 












TEK, WI, USA) set at 594/620nm (for calibration fluorescence - CF) or 
485/528nm (for substrate fluorescence - SF). The ‘blank’ (B) represented the 
cell fluorescence before treatment. The relative fluorescence (RF) was 
calculated as RF = (SF – B) / (CF – B). 
Topical drug absorption assay 
Mice were anesthetized with 2% isoflurane inhalation, and Rho-LNC-CH8 
(20 µL, containing 11 µg of CH8) were applied to a shaved dorsal area of 
approximately 1.5 cm2. At 0, 5, 15, 30, 60, 90, 120, 180, 240 and 300 min after 
application, fluorescence images of the whole animals were taken using an 
IVIS® Lumina Imaging System (Xenogen Corp, USA) with filters for rhodamine 
detection. A region of interest (ROI) was drawn 2 mm around the outer 
fluorescent margin, and the specific fluorescence was expressed as the 
difference between values for Rho-LNC-CH8 and LNC-CH8 surface radiance 
(photons/s/cm2) for each time point. As a fluorescence quenching/decay control, 
the same amount of Rho-LNC-CH8 was applied per cm2 onto an impermeable 
plastic blade and the fluorescence was measured as performed for animal skin.  
Mouse infection and topical treatment 
 Mice were infected in the ear with 2x106 promastigotes of L. 
amazonensis. On days 7 to 28 of infection, the ears were treated topically (5 
times a week, using a disposable spatula) with one of the following 
formulations: (1) 10 µg of CH8 in PBS/2% DMSO (CH8 group); (2) 10 µg of 
CH8 in LNC-CH8) (LNC-CH8 group); blank LNC (LNC group); or 20 µL of 2% 
DMSO alone (untreated group). At the end of treatment (day 30 post-infection), 
the animals were euthanized by terminal 5% isoflurane inhalation, the infected 












mL of complete M199 medium. The parasite burden was evaluated by a limiting 
dilution assay (LDA), as described previously26.  
Statistical analysis  
Data were analyzed by one-way or two-way ANOVA followed by 
Bonferroni multiple comparison test. Data were expressed as arithmetic mean ± 
standard deviation (SD) values and samples were considered significantly 




3.1 LNC efficiently encapsulates CH8 into homogeneous nanoparticle 
suspensions.  
 
All formulations were macroscopically homogeneous, and had unimodal 
narrow size dispersions, with mean diameters below 238 nm (laser diffraction) 
and 184 nm (PCS) (Table 1).  All nanocapsules showed a slight negative zeta 
potential () close to zero (-6.1 to -7.5 mV). The drug content was close to 500 
g/mL with an encapsulation efficiency close to 100% (99.9%) (Table 1). 
Overall, nanocapsule sizes and surface potential were slightly affected by the 
drug loading or rhodamine labeling. The high efficiency of drug encapsulation 
corroborate the previous results observed for other drugs, such as doxorubicin, 
tacrolimus, quercetin, resveratrol and curcumin16, 18, 27, 28.  
 
3.2 Rho-LNC-CH8 is internalized by L. amazonensis promastigotes   
 
To evaluate whether LNC could be internalized by parasite promastigote 
forms, these cells were incubated with Rho-LNC-CH8 (at 10 µg/mL of CH8) and 












fluorescence microscopy. Promastigotes internalized Rho-LNC-CH8 rapidly, 
and, within 15 minutes, a red fluorescence signal was observed in a specific 
sub-cellular compartment. Afterwards, at 60 min of internalization, the 
fluorescence signal appeared widespread in the cytoplasm. Quantification of the 
kinetics of Rho-LNC-CH8 internalization showed that the proportion of cells 
positive for Rho-LNC-CH8 increased with the incubation time (Figure 2), with 
~80% of promastigotes having internalized Rho-LNC-CH8 by 60 min of 
incubation. These data showed the nanosystem is efficiently internalized by the 
Leishmania form that initiates infection in mammalian hosts.  
 
3.3 CH8 encapsulation in LNCs did not decrease its anti-leishmanial 
activity. 
In a previous study, we demonstrated that CH8 has potent and selective 
activity against Leishmania promastigotes10. Here, we tested both CH8 and 
LNC-CH8 against the intracellular forms of the parasite, the amastigotes. 
Infected macrophages were incubated with CH8, LNC-CH8 or LNC and the 
number of amastigotes inside host cells was assessed by direct counting under 
a light microscope, after 48 h of treatment (Table 2). Entrapping of CH8 in LNCs 
did not alter the anti-amastigote activity of the compound in vitro, as both CH8 
and LNC-CH8 showed similar IC50 values (2.2 ± 0.1 and 2.9 ± 0.1 µg/mL, 
respectively). LNC (blank formulation) was not able to kill intracellular 
amastigotes (IC50 of 38.8 ± 0.3 µg/mL). However, LNC was not selective to the 
parasite, with encapsulation leading to a reduced selectivity index (SI) of CH8 













3.4 LNC-CH8 delivers CH8 to Leishmania amastigotes inside host cells. 
 Since encapsulation on LNCs did not alter the activity of CH8 in vitro, we 
evaluated the internalization of Rho-LNC-CH8 by infected and uninfected 
macrophages, to verify if the nanocapsules could deliver CH8 effectively to 
parasites inside macrophages, where the parasite survives and multiplies. For 
this purpose, bone marrow-derived macrophages (BMDM) infected with L. 
amazonensis promastigotes expressing GFP23 were incubated with Rho-LNC-
CH8 (10 µg/mL CH8), and the internalization was evaluated at different time 
points (up to 240 min), by fluorescence microscopy and flow cytometry (Figure 
3).  
Similarly to that observed in promastigotes, Rho-LNC-CH8 was 
internalized quickly by infected and uninfected BMDMs, and we observed red 
fluorescence in the macrophage cytoplasm (but not in the nucleus) within 15 
min of internalization (Figure 3A). In infected macrophages, the Rho-LNC-CH8 
red fluorescence appeared faster (at 7.5 min) than in uninfected cells (Figure 
3C), and internalization increased over time (Figure 3A and C). Importantly, the 
red fluorescence signal of Rho-LNC-CH8 was concentrated in the 
parasitophorous vacuole (PV) of infected cells (Figure 3A). Moreover, co-
localization of Rho-LNC-CH8 with GFP-labeled amastigotes in the PV could be 
observed after 60 and 120 min of incubation. After 240 min of incubation, the 
Rho-LNC-CH8 fluorescence was found predominantly co-localized with GFP-
labeled parasites in the PV, suggesting that Rho-LNC-CH8 had likely killed the 
amastigotes by that time point. In uninfected cells, the Rho-LNC-CH8 
fluorescence signal had decreased by 240 min of internalization, with only low 












percentage of fluorescent cells detected by flow cytometry (Figure 3A, B and C). 
This decrease in fluorescence at later time points was not observed in infected 
cells (Figure 3C). 
 Together, these results confirm that LNC-CH8 can be internalized by 
infected macrophages and delivered to the PV, the intracellular compartment 
where the parasite is located. 
 
3.5 LNC-CH8 triggers macrophage microbicidal mechanisms. 
Phagocytes such as macrophages are capable of responding to infection 
by triggering microbicidal mechanisms, which include the production of reactive 
oxygen species (ROS) and nitric oxide (NO), and the activation of proteolytic 
enzymes and acidification of the PV. To study the influence of entrapment into 
LNCs on the activation of macrophage microbicidal mechanisms by CH8, we 
evaluated the stimulation of these mechanisms – which constitutes macrophage 
activation - in infected cells treated with LNC-CH8. 
For ROS production, infected and uninfected macrophages were 
incubated with increasing concentrations of CH8, LNC-CH8 or LNC, and ROS 
production was assayed using the fluorescent dye H2DCFDA (Figure 4, A and 
B). As expected, Leishmania infection decreased the basal ROS levels in 
untreated cells. CH8 was unable to activate ROS production in macrophages, 
even at high concentrations. In contrast, both LNC and LNC-CH8 induced ROS 
production at medium to high concentrations (Figure 4A and B). 
In contrast, NO production (as estimated by NaNO2 quantification in 












LNC-CH8; however, LNC and CH8 could not stimulate NO production, even at 
high concentrations (Figure 4C and D). 
We assessed the proteolytic activity of macrophages by measuring the 
degradation of functionalized beads over time, in infected and uninfected cells 
treated with 1 µg/mL CH8, or equivalent amounts of LNC-CH8 and LNC. The 
proteolytic activity of uninfected cells was similar for all treatments (Figure 4E), 
while proteolysis levels increased over time in infected cells treated with LNC-
CH8 or LNC, but not CH8 alone (Figure 4F). Although the proteolytic response 
was delayed in infected compared with uninfected cells, treatment of the former 
with LNC or LNC-CH8 eventually increased proteolysis levels above those 
observed uninfected cells (Figure 4F). CH8 encapsulation in LNC did not 
change cell acidification significantly (as assessed using the LysoTracker Green 
dye), irrespective of the presence of infection (data not shown).  
The combined analysis of different antimicrobial mechanisms showed 
that LNC-CH8 can modulate host macrophage activation positively, which 
contributes to the activity of the LNC-CH8 nanosystem against the intracellular 
parasite.  
3.6 Rho-LNC-CH8 is absorbed efficiently by mouse skin. 
   
After the promising in vitro results described above, we evaluated if the 
LNC-CH8 formulation could permeate mouse skin and deliver the drug to 
macrophages in vivo. The kinetics of Rho-LNC-CH8 skin absorption was 
evaluated for up to 300 min after application onto the lightly shaved mouse 
hump. Although Rho-LNC-CH8 fluorescence was stable for up to 120 min after 
application, we observed a clear decrease in fluorescence thereafter until 240 












and B). Spontaneous fluorescence quenching by drying was discarded by 
surface radiance quantification demonstrating that the fluorescence intensity of 
Rho-LNC-CH8 applied onto an impermeable plastic surface remained stable 
throughout the experiment (Figure 5B).  
  
3.7 LNC-CH8 increased the efficacy of CH8 in cutaneous leishmaniasis 
treatment. 
 
Given that Rho-LNC-CH8 is absorbed by mouse skin, we tested the 
activity of LNC-CH8 in vivo as a topical treatment for experimental CL, in 
BALB/c mice infected in the ear with GFP-labeled L. amazonensis.  
After 3 weeks of daily topical treatment (5 days / week) with LNC, LNC-
CH8 or CH8 (10 µg CH8 per cm2/ dose), the parasite burden was evaluated in 
infected mouse ears by a limiting dilution assay. Mice treated with LNC-CH8 
had significantly fewer parasites in infected ears than animals either treated with 
CH8 alone, or kept untreated (Figure 6). Thus, encapsulation of CH8 in LNC-
CH8 increased its efficacy by the topical route in a murine model of CL. 
 
DISCUSSION 
In recent years, various topical formulations containing paromomycin, 
pentavalent antimonials, β-lapachone and amphotericin B have been developed 
for  CL treatment4-6, 29, but none were sufficiently effective or safe for clinical 
approval. Here, we evaluated the efficacy of a new topical nanoformulation 
against CL that combined the potency of a promising antileishmanial compound 













The results demonstrated that PCL and the oily component used here 
were adequate to provide a high rate of CH8 incorporation into LNC-CH8 
(99.9%). Most of the drug was probably retained into the lipid compartment, 
which is protected by the PCL shell, thus increasing its bioavailability, as 
demonstrated for oral quercetin and resveratrol16,31.  Despite their weak 
negative charge (-7.5 mV), LNC-CH8 stability was achieved by steric hindrance 
promoted by the nonionic polysorbate 80 surfactant32. 
  The resulting LNC-CH8 were readily taken up by both macrophages and 
promastigote forms of Leishmania. Light microscopy analysis of Rho-LNC-CH8 
internalization suggests that the nanocapsules enter promastigotes through the 
flagellar pocket and are transported to organelles of the endocytic pathway 
(likely corresponding to lysosome multivesicular tubules33) within 15 min, and 
then reach the cytoplasm. In macrophages, Rho-LNC-CH8 may reach the 
cytoplasm by fluid phase endocytosis, as described for LNC-doxorubicin28. 
Therefore, our data suggest that LNC-CH8 are only degraded after reaching the 
PV34, where Leishmania amastigotes reside. 
Encapsulation in LNC did not impair the anti-amastigote activity of CH8, 
as observed previously with poly(lactide-co-glycolide) (PLGA) microspheres that 
delayed intracellular parasite killing22. LNC may produce faster drug delivery to 
intracellular parasites due to their smaller size and/or higher sensitivity to 
lysosomal enzymes, compared with PLGA microspheres. The higher 
cytotoxicity of LNC-CH8 and LNC to macrophages, compared with CH8, is likely 
caused by the presence of polysorbate 80 surfactant in both LNC formulations. 
Despite the increased cytotoxicity, LNC-CH8 selectivity remained high - at 61 












DNDi as a ‘cut-off’ for promising new antiparasitic drugs35. Additionally, the 
polysorbate 80 cytotoxicity observed here may not be relevant in vivo, 
especially for topical administration, since intradermal polysorbate 80-containing 
LNC systems are safe to rats36.  
The innate immune response to parasitic infection leads to the production 
of ROS and NO which together generate peroxynitrite (ONOO-), a strong 
oxidant considered essential for parasite killing by phagocytic cells37. These 
compounds can also increase the expression of genes associated with pro-
inflammatory responses, such as NF-κB transcription factors38. While 
nanocarriers are known to activate these mechanisms,39,40 the LNC 
nanoparticles used in this studies only led to an increase in ROS species. 
Moreover, in line with the antioxidant and anti-inflammatory effects of 
chalcones40,41, CH8 alone could not activate macrophage antimicrobial 
mechanisms. in contrast, encapsulation into LNC led to ROS and NO 
production in both uninfected and infected cells. The former possibly accounting 
for the slightly increased macrophage cytotoxicity observed with LNC-CH8. 
Interestingly, intracellular Leishmania parasites downregulate these 
macrophage antimicrobial mechanisms2 and the use of LNC nanocarriers may 
help to overcome this effect. 
In addition to ROS and NO production, intracellular proteolysis is 
essential for microbial killing after endocytosis42. Interestingly, for safe 
therapeutic purposes, LNC-CH8 induced proteolytic activity in infected but not 
uninfected macrophages, suggesting that the presence of the parasites was 












The lower efficacy of previous topical formulations for CL is possibly due 
to lack of proper drug permeation through the stratum corneum barrier of the 
skin, necessary to reach the infected cells in the lower dermis layer30. Despite 
its low molecular weight (329Da) and high lipophilicity (LogP = 3.63), CH8 alone 
cannot permeate the skin barrier43. However, the imaging studies shown here 
demonstrate that Rho-LNC-CH8 applied onto the mouse skin surface is no 
longer detectable 3 hours post-application, suggesting that the drug is absorbed 
efficiently by the skin. The time required for skin signal decrease suggests that 
drug absorption is not due to occlusion, as reported previously for solid lipid 
nanoparticles44. Rho-LNC-CH8 and LNC-CH8 permeation through skin 
appendages (hair follicles or sweat glands)30 a pears more plausible. This is 
agreement with the studies of Raber et al45 demonstrating that negatively 
charged nanoparticles are able to interact more efficiently with the skin surface, 
facilitating follicular uptake.   
Although the mechanism by which LNC-CH8 promotes drug permeation 
through the skin remains unclear, the in vivo data in murine CL clearly show 
that topical application of LNC-CH8 onto mouse lesions effectively reduced the 
parasite load by ~80% in comparison with free CH8. Interestingly, LNC alone 
reduced the number of parasites in skin lesions by ~30%. Although blank LNC 
does not have intrinsic antiparasitic activity, as seen by the lack of in vitro 
activity, our data suggest that this blank nanodevice is an excellent adjuvant for 
topical CL treatment. LNC-CH8 was more effective than other nanosystems 
attempted for CL topical treatment29, 46.  Following the skin permeating potential 
demonstrated here, future LNC-CH8 manipulations may further improve its 












superparamagnetic iron oxide nanoparticles (SPIONs) to allow heating and 
killing of the infected cells after local application of a magnetic field, as 
envisaged for cancer thermotherapy47. 
Overall, the results reported here show that LNC-CH8 is an appropriate 
nanosystem not only for intracellular drug delivery, but also for skin permeation 
and intracellular parasite killing.  This study has clinical relevance for localized 
and safe treatment of CL, a skin pathology for which there is currently no 
adequate topical treatments. 
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Figure 1. Chemical structure of the chalcone CH8. 
Figure 2. Kinetics of Rho-LNC-CH8 internalization by promastigotes. 
Leishmania amazonensis promastigotes were incubated with rhodamine-
labeled LNC-CH8 (Rho-LNC-CH8, at 10 µg/mL CH8) and analyzed at different 
time points, to detect compound internalization. (A) Light microscopy analysis of 
live promastigotes, showing internalization of red-fluorescent Rho-LNC-CH8 












5 µm. (B, C) Flow cytometry analysis of the Rho-LNC-CH8 fluorescence 
intensity in promastigotes (105 events/sample) at different time points, displayed 
as histograms (B) and as the percentage of cells expressing > 6 x 100 arbitrary 
units of fluorescence (C; corresponding to cells in gate M1, in B). AU, arbitrary 
units. (n=3). 
Figure 3. Rho-LNC-CH8 is efficiently internalized by macrophages. Bone 
marrow derived macrophages (BMDM) were infected with L. amazonensis 
expressing GFP and incubated with Rho-LNC-CH8 (10 μg/mL CH8). (A) Light 
microscopy analysis of uninfected and infected BMDM at different time points of 
incubation with Rho-LNC-CH8, showing co-localization between amastigotes (in 
green) and Rho-LNC-CH8 (in red), after 120 min of incubation. DIC, differential 
interference contrast. Scale bar, 20 µm. (B, C) Flow cytometry analysis of 
uninfected and infected BMDM after 240 min of Rho-LNC-CH8 internalization. 
The histograms in B show treated cells in blue, and untreated in grey, and the 
percentage of cells expressing >3 x 100 arbitrary fluorescence units (gate M1 in 
B) is shown in C (mean ± SD values, n=3 independent experiments). *p<0.05. 
AU, arbitrary units. 
Figure 4. LNC-CH8 (but not CH8 alone) activates infected macrophages. 
Bone marrow derived macrophages (BMDM) were kept uninfected (A, C, E) or 
were infected with L. amazonensis (B, D, F), treated with LNC, CH8 or LNC-
CH8 and then processed for the analysis of different markers of macrophage 
activation. (A, B) Reactive oxygen species (ROS) production was measured 
fluorimetrically using H2DCFDA, after 30 min of treatment. FU, fluorescence 
units (C, D) Nitric oxide (NO) levels were estimated by quantifying NaNO2 in 












Intracellular proteolysis was assessed by using DQ green-BSA and IgG-
functionalized beads, after 30 min of treatment. Results are expressed as 
relative fluorescence (RF). Data represent mean ± SD values (n=3 independent 
experiments). *p < 0.05, **p < 0.01, relative to free CH8. 
Figure 5. Topical Rho-LNC-CH8 is absorbed through living mouse skin. 
Rhodamine-labeled CH8 (Rho-LNC-CH8, with 10 µg/mL CH8) was applied onto 
the pre-shaved dorsum of BALB/c mice and the skin fluorescence kinetics was 
followed by in vivo fluorescent imaging using the IVIS® Lumina system (A). A 
region of interest (ROI) was drawn 2 mm around the outer fluorescent margin, 
and data expressed as average surface radiance (photons/s/cm2) after 
deduction of background fluorescence of skin to which unlabeled LNC-CH8 was 
applied (red line). As a control for fluorescence quenching/decay, the same 
amount of Rho-LNC-CH8 or LNC-CH8 was applied onto an impermeable 
surface (blue line) (B). Means ± SD values (n=5). 
Figure 6. Efficacy of topical LNC-CH8 against cutaneous leishmaniasis. 
BALB/c mice were infected in the left ear with 2x106 promastigotes of L. 
amazonensis. Seven days after infection, the infected ears were treated 
topically once a day (five times a week), for 3 weeks, with 20 µL of LNC, LNC-
CH8 containing 10 µg of CH8 (22.5 µg CH8 per cm2) or the same amount of 
free CH8 in PBS/2% DMSO. The untreated group was administered only the 
drug-free vehicle. After 30 days of infection, animals were euthanized, the ears 
were removed and the parasite burden was quantified by a limiting dilution 
assay. Data represent mean ± SD values of one out of two independent 

















Table 1. Physicochemical features of the different nanocapsules. 
LNC, “blank” LNC; LNC-CH8, LNC entrapping CH8; Rho-LNC-CH8, LNC-CH8 produced using a 
rhodamine(Rho)-labelled precursor. , zeta potential; EE, Encapsulation Efficiency.  (n=3). 









LNC 167 ± 0.009  1.20 ± 0.1 -6.10 ± 0.09 181± 09 0.12 ± 0.01 - - 
LNC-CH8 238 ± 0.010 0.81 ± 0.1 -7.50 ± 0.07 174 ± 07 0.10 ± 0.01 501 ± 0.02 99.9 






















Table 2. Anti-Leishmania activity of LNC-CH8 in vitro.  
IC50, anti-amastigote activity estimated by light microscopy. CC50, cytotoxicity estimated 











 (µg/mL) SI 
CH8   2.15 ± 0.14 393.72 ± 0.09 183.1 
LNC 38.83 ± 0.29 247.90 ± 0.06 6.3 













The antileishmanial drug candidate CH8 was encapsulated in lipid-core 
nanocapsules (LNC-CH8), to improve drug bioavailability for topical treatment of 
cutaneous leishmaniasis. LNC-CH8 were able to control the infection by 
penetrating mouse skin and delivering the drug to infected dermal 
macrophages. 
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